Charles River Laboratories (CRL) Tops Q2 EPS by 40c; lowers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $351.87 +3.94%
EPS Growth %: +22.2%
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
FUSE, INM, TRI, More
EPS Growth %: +22.2%
Financial Fact:
Cost of products sold: 69.33M
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.80, $0.40 better than the analyst estimate of $2.40. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $9.90-$10.20, versus the consensus of $10.99.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Comscore (SCOR) Misses Q3 EPS by 446c
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
